Effect of longer health service provider delays on stage at diagnosis and mortality in symptomatic breast cancer
- PMID: 25753211
- DOI: 10.1016/j.breast.2015.02.027
Effect of longer health service provider delays on stage at diagnosis and mortality in symptomatic breast cancer
Abstract
Purpose: This study explored whether longer provider delays (between first presentation and treatment) were associated with later stage and poorer survival in women with symptomatic breast cancer.
Methods: Data from 850 women with symptomatic breast cancer were linked with the Scottish Cancer Registry; Death Registry; and hospital discharge dataset. Logistic regression and Cox survival analyses with restricted cubic splines explored relationships between provider delays, stage and survival, with sequential adjustment for patient and tumour factors.
Results: Although confidence intervals were wide in both adjusted analyses, those with the shortest provider delays had more advanced breast cancer at diagnosis. Beyond approximately 20 weeks, the trend suggests longer delays are associated with more advanced stage, but is not statistically significant. Those with symptomatic breast cancer and the shortest presentation to treatment time (within 4 weeks) had the poorest survival. Longer time to treatment was not significantly associated with worsening mortality.
Conclusions: Poor prognosis patients with breast cancer are being triaged for rapid treatment with limited effect on outcome. Prolonged time to treatment does not appear to be strongly associated with poorer outcomes for patients with breast cancer, but the power of this study to assess the effect of very long delays (>25 weeks) was limited. Efforts to reduce waiting times are important from a quality of life perspective, but tumour biology may often be a more important determinant of stage at diagnosis and survival outcome.
Keywords: Breast cancer; Cancer staging; Delayed diagnosis; Diagnosis; Health services; Survival.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Time from first presentation in primary care to treatment of symptomatic colorectal cancer: effect on disease stage and survival.Br J Cancer. 2014 Jul 29;111(3):461-9. doi: 10.1038/bjc.2014.352. Epub 2014 Jul 3. Br J Cancer. 2014. PMID: 24992583 Free PMC article.
-
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer.Br J Cancer. 1999 Feb;79(5-6):858-64. doi: 10.1038/sj.bjc.6690137. Br J Cancer. 1999. PMID: 10070881 Free PMC article.
-
Aspects of survival from colorectal cancer in Denmark.Dan Med J. 2012 Apr;59(4):B4428. Dan Med J. 2012. PMID: 22459726
-
22. Diagnostic delays in breast cancer and impact on survival.Int J Clin Pract. 2003 Apr;57(3):200-3. Int J Clin Pract. 2003. PMID: 12723724 Review.
-
Influence of delay on survival in patients with breast cancer: a systematic review.Lancet. 1999 Apr 3;353(9159):1119-26. doi: 10.1016/s0140-6736(99)02143-1. Lancet. 1999. PMID: 10209974
Cited by
-
Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.Health Technol Assess. 2020 Nov;24(66):1-332. doi: 10.3310/hta24660. Health Technol Assess. 2020. PMID: 33252328 Free PMC article.
-
The influence on survival of delay in the treatment initiation of screening detected non-symptomatic breast cancer.Sci Rep. 2019 Jul 15;9(1):10158. doi: 10.1038/s41598-019-46736-1. Sci Rep. 2019. PMID: 31308467 Free PMC article.
-
A cancer geography paradox? Poorer cancer outcomes with longer travelling times to healthcare facilities despite prompter diagnosis and treatment: a data-linkage study.Br J Cancer. 2017 Jul 25;117(3):439-449. doi: 10.1038/bjc.2017.180. Epub 2017 Jun 22. Br J Cancer. 2017. PMID: 28641316 Free PMC article.
-
Racial Disparities in Diagnostic Delay Among Women With Breast Cancer.J Am Coll Radiol. 2021 Oct;18(10):1384-1393. doi: 10.1016/j.jacr.2021.06.019. Epub 2021 Jul 17. J Am Coll Radiol. 2021. PMID: 34280379 Free PMC article.
-
Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data.BMJ Open. 2022 Dec 15;12(12):e059669. doi: 10.1136/bmjopen-2021-059669. BMJ Open. 2022. PMID: 36521881 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical